ReCell approved in China
Thursday, 03 July, 2008
The Chinese State Food and Drug Administration (SFDA) has granted approval to register Avita Medical's (ASX: AVH) ReCell cell harvesting device on the Chinese market.
The product will be marketed by Helicon Group (ASX: HCG), a WA-headquartered pharmaceutical marketing company specialising in introducing registered medical products into niche markets in China.
The SFDA has approved the product concept and the ReCell kit, but Helicon said there were some importation issues to be overcome before it is on the market.
Helicon has also recently acquired the exclusive licensing rights from EUSA Pharma for Collatamp, an implantable collagen device for the delivery of antibiotics to surgical sites, and is preparing a submission to the SFDA for registration.
Avita Medical was formerly known as Clinical Cell Culture.
Defective sperm doubles pre-eclampsia risk in IVF patients
A high proportion of the father's spermatozoa possessing DNA strand breaks is associated with...
Free meningococcal B vaccines coming to the NT
The Northern Territory Government has confirmed the rollout of a free meningococcal B vaccine...
Mouth bacteria linked to increased head and neck cancer risk
More than a dozen bacterial species that live in people's mouths have been linked to a...
